Literature DB >> 9707007

Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes.

A Maeda1, M Honda, T Kuramochi, T Takabatake.   

Abstract

We examined intracellular calcium transients of isolated single cardiac myocytes from rats with doxorubicin (DOX)-induced cardiomyopathy with simultaneous measurement of cell motion. DOX was administered i.p. to Sprague-Dawley rats at 2.5 mg/kg once a week for 10 weeks. Field-stimulated calcium transients and simultaneous cell motion in single myocytes were measured in the presence or absence of isoproterenol using fura-2/AM. Histopathologic examination revealed slight changes. The time courses of both calcium transients and cell motion were significantly prolonged by DOX. There was a slight but not significant reduction in parameters of contractility in both calcium transients and cell motion. The beta-adrenoceptor responsiveness of both calcium transients and cell motion was not significantly impaired compared with the controls. Our data indicated that, despite the slight histologic changes in the heart in DOX-induced cardiomyopathy, impaired sequestration of intracellular free calcium ions in individual myocytes may be one factor leading to diastolic dysfunction. Monitoring of diastolic function is important to detect early cardiotoxicity caused by DOX.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707007     DOI: 10.1253/jcj.62.505

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  12 in total

1.  How could we solve the diagnostic dilemma of doxorubicin toxicity in high-risk patients?

Authors:  Vedat Davutoglu; Serdar Soydinc; Ilyas Akdemir
Journal:  J Natl Med Assoc       Date:  2004-05       Impact factor: 1.798

2.  Anthracycline-induced cardiomyopathy: The search continues.

Authors:  Agnes S Kim; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2015-12-08       Impact factor: 5.952

3.  Molecular biology of doxorubicin-induced cardiomyopathy.

Authors:  J Umlauf; M Horký
Journal:  Exp Clin Cardiol       Date:  2002

4.  Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

Authors:  R Zucchi; G Yu; S Ghelardoni; F Ronca; S Ronca-Testoni
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

6.  Effects of fructose-1,6-diphosphate on concentration of calcium and activities of sarcoplosnic Ca2+-ATPase in cardiomyocytes of Adriamycin-treated rats.

Authors:  Wei Cai; Jun-zhu Chen; Li-ming Ruan; Yi-na Wang
Journal:  J Zhejiang Univ Sci B       Date:  2005-07       Impact factor: 3.066

7.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry.

Authors:  Fabio Cerignoli; David Charlot; Ross Whittaker; Randy Ingermanson; Piyush Gehalot; Alex Savchenko; David J Gallacher; Rob Towart; Jeffrey H Price; Patrick M McDonough; Mark Mercola
Journal:  J Pharmacol Toxicol Methods       Date:  2012-08-25       Impact factor: 1.950

9.  TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.

Authors:  Alexandra Berdichevski; Gideon Meiry; Felix Milman; Irena Reiter; Oshra Sedan; Sivan Eliyahu; Heather S Duffy; Moussa B Youdim; Ofer Binah
Journal:  J Pharmacol Exp Ther       Date:  2009-11-13       Impact factor: 4.030

Review 10.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.